NYSE:IQV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$47.9b

Last Updated

2021/08/03 23:36 UTC

Data Sources

Company Financials +

Executive Summary

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More Details


Snowflake Analysis

High growth potential with proven track record.


Similar Companies

Share Price & News

How has IQVIA Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IQV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: IQV's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

2.8%

IQV

3.0%

US Life Sciences

0.9%

US Market


1 Year Return

56.1%

IQV

42.8%

US Life Sciences

34.7%

US Market

Return vs Industry: IQV exceeded the US Life Sciences industry which returned 40.9% over the past year.

Return vs Market: IQV exceeded the US Market which returned 34.4% over the past year.


Shareholder returns

IQVIndustryMarket
7 Day2.8%3.0%0.9%
30 Day0.3%4.6%0.2%
90 Day7.8%15.2%4.7%
1 Year56.1%56.1%43.0%42.8%36.8%34.7%
3 Year103.5%103.5%114.8%113.7%62.5%52.4%
5 Year226.8%226.8%235.6%231.7%123.1%98.4%

Long-Term Price Volatility Vs. Market

How volatile is IQVIA Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IQVIA Holdings undervalued compared to its fair value and its price relative to the market?

22.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IQV ($249.97) is trading below our estimate of fair value ($322.5)

Significantly Below Fair Value: IQV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IQV is poor value based on its PE Ratio (78.8x) compared to the US Life Sciences industry average (46.6x).

PE vs Market: IQV is poor value based on its PE Ratio (78.8x) compared to the US market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: IQV is poor value based on its PEG Ratio (3.1x)


Price to Book Ratio

PB vs Industry: IQV is overvalued based on its PB Ratio (8.3x) compared to the US Life Sciences industry average (6x).


Future Growth

How is IQVIA Holdings forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

25.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IQV's forecast earnings growth (25.5% per year) is above the savings rate (2%).

Earnings vs Market: IQV's earnings (25.5% per year) are forecast to grow faster than the US market (15% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: IQV's revenue (9.3% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: IQV's revenue (9.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IQV's Return on Equity is forecast to be high in 3 years time (24.2%)


Past Performance

How has IQVIA Holdings performed over the past 5 years?

-6.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IQV has high quality earnings.

Growing Profit Margin: IQV's current net profit margins (4.7%) are higher than last year (1.2%).


Past Earnings Growth Analysis

Earnings Trend: IQV's earnings have declined by 6.1% per year over the past 5 years.

Accelerating Growth: IQV's earnings growth over the past year (359.8%) exceeds its 5-year average (-6.1% per year).

Earnings vs Industry: IQV earnings growth over the past year (359.8%) exceeded the Life Sciences industry 51.4%.


Return on Equity

High ROE: IQV's Return on Equity (10.9%) is considered low.


Financial Health

How is IQVIA Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IQV's short term assets ($5.1B) exceed its short term liabilities ($4.8B).

Long Term Liabilities: IQV's short term assets ($5.1B) do not cover its long term liabilities ($13.4B).


Debt to Equity History and Analysis

Debt Level: IQV's debt to equity ratio (211.3%) is considered high.

Reducing Debt: IQV had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: IQV's debt is well covered by operating cash flow (22.4%).

Interest Coverage: IQV's interest payments on its debt are not well covered by EBIT (3x coverage).


Balance Sheet


Dividend

What is IQVIA Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IQV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IQV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IQV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IQV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: IQV is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IQV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Ari Bousbib (60 yo)

4.83yrs

Tenure

US$25,575,986

Compensation

Mr. Ari Bousbib serves as Chairman and Chief Executive Officer at IQVIA Holdings Inc. since October 2016 and also serves as its President. He has been the Chairman, Chief Executive Officer and President of...


CEO Compensation Analysis

Compensation vs Market: Ari's total compensation ($USD25.58M) is above average for companies of similar size in the US market ($USD11.16M).

Compensation vs Earnings: Ari's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: IQV's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: IQV's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

IQVIA Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IQVIA Holdings Inc.
  • Ticker: IQV
  • Exchange: NYSE
  • Founded: 1982
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$47.899b
  • Shares outstanding: 191.61m
  • Website: https://www.iqvia.com

Number of Employees


Location

  • IQVIA Holdings Inc.
  • 83 Wooster Heights Road
  • Danbury
  • Connecticut
  • 6810
  • United States

Listings


Biography

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates throug...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/03 23:36
End of Day Share Price2021/08/03 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.